Neuroprotective Effects

Preclinical studies, such as those reviewed in a paper published in Current Pharmaceutical Design, indicate that cannabinoids have neuroprotective properties, potentially offering benefits in neurodegenerative diseases like Alzheimer's and Parkinson's.

While research on the potential benefits of medicinal cannabis in treating Alzheimer's disease and Parkinson's disease is ongoing, there are studies exploring its effects on symptoms associated with these neurodegenerative disorders.

One study examining the effects of cannabinoids in Parkinson's disease was published in the Journal of Psychopharmacology in 2014.

Parkinson's Disease

A randomized, double-blind, placebo-controlled trial investigated the effects of a cannabis extract containing THC and CBD on motor symptoms in patients with Parkinson's disease.

The study found that treatment with the cannabis extract led to significant improvements in motor function and overall well-being compared to placebo. Additionally, patients experienced a reduction in levodopa-induced dyskinesias, a common side effect of Parkinson's disease medication.

However, further research is needed to confirm these findings and explore the long-term effects of cannabis-based treatments on Parkinson's disease progression.

Alzheimer's Disease

In Alzheimer's disease, preclinical studies have shown that cannabinoids, particularly CBD, may have neuroprotective effects and reduce neuroinflammation associated with the disease.

Additionally, some research suggests that cannabinoids could improve behavioural symptoms such as agitation and aggression in Alzheimer's patients.

However, large-scale clinical trials are needed to validate these findings and determine the efficacy and safety of cannabis-based treatments for Alzheimer's disease.